The U.S. needs a more constructive and inclusive approach to the challenge of affording high-quality medicines. In a column this summer, I argued for an agenda focused on reducing out-of-pocket costs to patients, elevating value as the preeminent criteria in pricing medicines, and increasing competition among medicines. I’ve been offering some ideas along these lines in recent columns, and here will look at the importance of recognizing and rewarding value.
Read Full Article »